Kemadrin

Basic Kemadrin information

• INN (international nonproprietary name): Procyclidine (procyclidine hydrochloride)
• Brand names available in the United Kingdom: Kemadrin (tablets 5 mg); procyclidine is also available as generics
• ATC code: N04AA04 (anti-Parkinson drugs; anticholinergic agents; tertiary amines)
• Forms and dosages: tablets 5 mg; oral solution 2.5 mg/5 ml and 5 mg/5 ml
• Manufacturers in the United Kingdom: Aspen Pharma (UK) and generic suppliers such as Teva and Mylan
• Registration status in the United Kingdom: Authorised by the MHRA; prescription-only medicine (POM)
• OTC / Rx classification: Prescription-only medicine (POM)

Where Kemadrin sits

Procyclidine is classified under ATC code N04AA04 as an anticholinergic anti‑Parkinson agent.

Kemadrin 5 mg tablets are the most common form; the MHRA authorises Kemadrin in the UK and it is a prescription-only medicine.

Legal status and availability in the UK

Kemadrin is a prescription-only medicine (POM) in the UK.

In our online pharmacy, Kemadrin is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Dosage, regimens and administration

Standard dosages by indication

For idiopathic Parkinson’s disease the usual adult dose is 2.5–5 mg three times daily.

Titrate to clinical effect with a maximum total daily dose sometimes reaching up to 30 mg in divided doses as needed.

For drug‑induced extrapyramidal symptoms a range of 2.5–10 mg per day in divided doses is commonly used and should be adjusted to the minimum effective dose.

Acute dystonia is usually treated with a single dose of 5 mg given orally or intramuscularly, with one repeat dose after 20 minutes if required in acute settings.

Children are not commonly prescribed procyclidine except brief specialist‑supervised use for rare acute reactions.

Elderly patients should start at the lowest possible dose and be titrated slowly.

Missed dose and overdose guidance

If a dose is missed take it as soon as remembered unless it is close to the next scheduled dose.

Do not double up doses to make up for a missed dose.

Overdose produces anticholinergic toxicity such as agitation, hallucinations, urinary retention and hyperthermia.

Urgent medical assessment is required in suspected overdose and treatment is supportive; physostigmine may be used in hospital settings where appropriate.

Indications and clinical positioning

Approved and common off‑label uses

Kemadrin is indicated for symptomatic relief in Parkinson’s disease, particularly when tremor predominates.

The medicine is also used to treat drug‑induced extrapyramidal side effects from antipsychotic therapy.

Acute dystonic reactions are another recognised indication where a rapid single dose can be effective.

Procyclidine is not disease‑modifying and provides symptomatic control only.

How Kemadrin fits in treatment pathways

Prescribers may choose Kemadrin when tremor is a dominant symptom or to rapidly treat EPS caused by antipsychotics.

Alternatives include other anticholinergics such as trihexyphenidyl, biperiden or benztropine and non‑anticholinergic options such as amantadine or levodopa/carbidopa for broader Parkinson’s control.

For long‑term management of Parkinson’s, clinicians often prefer levodopa regimens due to the anticholinergic burden of drugs like Kemadrin.

Contraindications and precautions

Absolute contraindications (do not use)

Do not use procyclidine in patients with known hypersensitivity to procyclidine or any excipient.

Narrow‑angle glaucoma is an absolute contraindication because anticholinergics can raise intraocular pressure.

Obstructive uropathy such as advanced prostatic hypertrophy with urinary retention is a contraindication.

Gastrointestinal obstruction is another absolute contraindication.

Conditions requiring caution or specialist review

Elderly patients require careful consideration because of the risk of confusion and falls; start low and review frequently.

Patients with significant cardiac disease, severe hepatic or renal impairment, psychiatric illness or myasthenia gravis need specialist review before starting.

Pregnancy and breastfeeding should prompt a risk/benefit discussion; use only if clearly needed.

1. Contraindication → Rationale/Action: Narrow‑angle glaucoma → avoid use and refer to ophthalmology if needed.
2. Contraindication → Rationale/Action: Obstructive uropathy → do not prescribe; consider urology review.

Side effects, monitoring and risk mitigation

Common, dose‑related adverse effects

Anticholinergic effects are the most frequent: dry mouth, blurred vision, constipation and urinary retention.

CNS effects include drowsiness, dizziness and confusion, particularly in older adults.

Other recognised effects are tachycardia and increased intraocular pressure.

Most adverse effects are dose‑dependent and reversible on withdrawal of the medicine.

Monitoring recommendations and deprescribing tips

Baseline assessment should include cognitive status and bladder function, especially in frail older people.

Consider measuring intraocular pressure in patients at risk of glaucoma and perform a falls risk assessment for elderly patients.

Pharmacists should counsel on managing dry mouth and constipation and advise immediate GP review for urinary retention or marked confusion.

Deprescribing should be gradual where possible and coordinated with neurology or psychiatry for patients treated for EPS.

Drug interactions and polypharmacy considerations

Major interaction classes

Additive anticholinergic burden is the primary interaction concern when Kemadrin is combined with other antimuscarinics.

CNS‑depressant drugs such as benzodiazepines, opioids or alcohol can increase drowsiness and impairment when used together.

Patients with impaired hepatic or renal function may have reduced clearance and higher exposure, increasing toxicity risk.

Co‑administration with other drugs that raise heart rate or intraocular pressure warrants caution.

Practical interaction checks

Perform an anticholinergic burden screen on repeat prescriptions and flag duplicative antimuscarinics.

Check the medication record for sedative medicines and counsel patients to avoid alcohol.

When in doubt contact the prescriber to review alternatives or dose reduction strategies.

Special populations: elderly, pregnancy, children

Guidance for older adults and frailty

Older adults are particularly susceptible to cognitive impairment, delirium and falls from anticholinergic drugs.

Start at the lowest effective dose and schedule frequent medication reviews with the GP or frailty team.

Consider non‑anticholinergic alternatives or specialist referral where possible.

Carers should be counselled to monitor for confusion, reduced oral intake and changes in mobility.

Use in pregnancy, breastfeeding and paediatrics

Safety data in pregnancy and breastfeeding are limited and procyclidine should be used only if clearly essential after weighing risks and benefits.

Paediatric use is uncommon and generally restricted to short‑term specialist management of acute dystonia.

Storage and handling

Storage

Store Kemadrin at room temperature between 15–25°C and protect from moisture and excessive heat.

No refrigeration is required for tablets or standard oral solutions.

Frequently asked questions

What is Kemadrin used for? Kemadrin is used for Parkinson’s tremor relief and for treating antipsychotic‑related EPS.

Is it available on the NHS? It is a prescription-only medicine and is commonly prescribed on NHS prescriptions.

How long until it works? Many patients report improvement within days for EPS or tremor.

Can I drive while taking it? Avoid driving if you feel drowsy or your vision is blurred.

Red flags and when to seek urgent care

Red flags include severe confusion, urinary retention, very high temperature or seizures.

Advise immediate medical attention or calling 999 if these symptoms occur.

Delivery across the United Kingdom